The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides
Authors
Keywords
-
Journal
Scientific Reports
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-11-16
DOI
10.1038/srep16541
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
- (2014) Eric Karran et al. ANNALS OF NEUROLOGY
- Lessons from a Failed γ-Secretase Alzheimer Trial
- (2014) Bart De Strooper CELL
- Ushering in the study and treatment of preclinical Alzheimer disease
- (2013) Jessica B. Langbaum et al. Nature Reviews Neurology
- Gamma-Secretase Inhibitor Activity of aPterocarpus erinaceusExtract
- (2013) Salim Hage et al. Neurodegenerative Diseases
- Presenilins and -Secretase: Structure, Function, and Role in Alzheimer Disease
- (2013) B. De Strooper et al. Cold Spring Harbor Perspectives in Medicine
- Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea racemosa
- (2012) Mark A. Findeis et al. ACS Chemical Neuroscience
- Alzheimer’s Disease, Cholesterol, and Statins: The Junctions of Important Metabolic Pathways
- (2012) Tiago Silva et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Drug repositioning for Alzheimer's disease
- (2012) Anne Corbett et al. NATURE REVIEWS DRUG DISCOVERY
- New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs
- (2011) Salvatore Salomone et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
- (2011) R. Huang et al. Science Translational Medicine
- NerveCenter: New evidence of preserved cognition in unresponsive TBI patient raises questions, concerns
- (2010) Kurt Samson ANNALS OF NEUROLOGY
- Novel γ-secretase inhibitors uncover a common nucleotide-binding site in JAK3, SIRT2, and PS1
- (2010) Fang Wu et al. FASEB JOURNAL
- Tarenflurbil for Alzheimer's disease: a “shot on goal” that missed
- (2010) Bruno Vellas LANCET NEUROLOGY
- An APP inhibitory domain containing the Flemish mutation residue modulates γ-secretase activity for Aβ production
- (2010) Yuan Tian et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Alzheimer's Disease: From Pathology to Therapeutic Approaches
- (2009) Roland Jakob-Roetne et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Herbals in the control of ageing
- (2009) Vijay K. Kapoor et al. DRUG DISCOVERY TODAY
- Recent Advances in the Identification of γ-Secretase Inhibitors To Clinically Test the Aβ Oligomer Hypothesis of Alzheimer’s Disease
- (2009) Anthony F. Kreft et al. JOURNAL OF MEDICINAL CHEMISTRY
- Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements
- (2008) Matthew L Hemming et al. PLOS BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started